Literature DB >> 19201763

Mutations in CLN7/MFSD8 are a common cause of variant late-infantile neuronal ceroid lipofuscinosis.

Maria Kousi1, Eija Siintola, Lenka Dvorakova, Hana Vlaskova, Julie Turnbull, Meral Topcu, Deniz Yuksel, Sarenur Gokben, Berge A Minassian, Milan Elleder, Sara E Mole, Anna-Elina Lehesjoki.   

Abstract

The neuronal ceroid lipofuscinoses (NCLs), the most common neurodegenerative disorders of childhood, are characterized by the accumulation of autofluorescent storage material mainly in neurons. Although clinically rather uniform, variant late-infantile onset NCL (vLINCL) is genetically heterogeneous with four major underlying genes identified so far. We evaluated the genetic background underlying vLINCL in 119 patients, and specifically analysed the recently reported CLN7/MFSD8 gene for mutations in 80 patients. Clinical data were collected from the CLN7/MFSD8 mutation positive patients. Eight novel CLN7/MFSD8 mutations and seven novel mutations in the CLN1/PPT1, CLN2/TPP1, CLN5, CLN6 and CLN8 genes were identified in patients of various ethnic origins. A significant group of Roma patients originating from the former Czechoslovakia was shown to bear the c.881C>A (p.Thr294Lys) mutation in CLN7/MFSD8, possibly due to a founder effect. With one exception, the CLN7/MFSD8 mutation positive patients present a phenotype indistinguishable from the other vLINCL forms. In one patient with an in-frame amino acid substitution mutation in CLN7/MFSD8, the disease onset was later and the disease course less aggressive than in variant late-infantile NCL. Our findings raise the total number of CLN7/MFSD8 mutations to 14 with the majority of families having private mutations. Our study confirms that CLN7/MFSD8 defects are not restricted to the Turkish population, as initially anticipated, but are a relatively common cause of NCL in different populations. CLN7/MFSD8 should be considered a diagnostic alternative not only in variant late-infantile but also later onset NCL forms with a more protracted disease course. A significant number of NCL patients in Turkey exist, in which the underlying genetic defect remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19201763     DOI: 10.1093/brain/awn366

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   15.255


  37 in total

Review 1.  Classification and natural history of the neuronal ceroid lipofuscinoses.

Authors:  Jonathan W Mink; Erika F Augustine; Heather R Adams; Frederick J Marshall; Jennifer M Kwon
Journal:  J Child Neurol       Date:  2013-07-09       Impact factor: 1.987

Review 2.  Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses.

Authors:  R Kohan; I A Cismondi; A M Oller-Ramirez; N Guelbert; Tapia V Anzolini; G Alonso; S E Mole; Dodelson R de Kremer; Noher I de Halac
Journal:  Curr Pharm Biotechnol       Date:  2011-06       Impact factor: 2.837

3.  Kufs disease, the major adult form of neuronal ceroid lipofuscinosis, caused by mutations in CLN6.

Authors:  Todor Arsov; Katherine R Smith; John Damiano; Silvana Franceschetti; Laura Canafoglia; Catherine J Bromhead; Eva Andermann; Danya F Vears; Patrick Cossette; Sulekha Rajagopalan; Alan McDougall; Vito Sofia; Michael Farrell; Umberto Aguglia; Andrea Zini; Stefano Meletti; Michela Morbin; Saul Mullen; Frederick Andermann; Sara E Mole; Melanie Bahlo; Samuel F Berkovic
Journal:  Am J Hum Genet       Date:  2011-05-05       Impact factor: 11.025

4.  Expression and lysosomal targeting of CLN7, a major facilitator superfamily transporter associated with variant late-infantile neuronal ceroid lipofuscinosis.

Authors:  A Sharifi; M Kousi; C Sagné; G C Bellenchi; L Morel; M Darmon; H Hulková; R Ruivo; C Debacker; S El Mestikawy; M Elleder; A-E Lehesjoki; A Jalanko; B Gasnier; A Kyttälä
Journal:  Hum Mol Genet       Date:  2010-09-07       Impact factor: 6.150

5.  Novel allelic variants and evidence for a prevalent mutation in URAT1 causing renal hypouricemia: biochemical, genetics and functional analysis.

Authors:  Blanka Stiburkova; Ivan Sebesta; Kimiyoshi Ichida; Makiko Nakamura; Helena Hulkova; Vladimir Krylov; Lenka Kryspinova; Helena Jahnova
Journal:  Eur J Hum Genet       Date:  2013-02-06       Impact factor: 4.246

6.  The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations.

Authors:  Helena Poupetová; Jana Ledvinová; Linda Berná; Lenka Dvoráková; Viktor Kozich; Milan Elleder
Journal:  J Inherit Metab Dis       Date:  2010-05-20       Impact factor: 4.982

7.  Early-onset Lafora body disease.

Authors:  Julie Turnbull; Jean-Marie Girard; Hannes Lohi; Elayne M Chan; Peixiang Wang; Erica Tiberia; Salah Omer; Mushtaq Ahmed; Christopher Bennett; Aruna Chakrabarty; Atul Tyagi; Yan Liu; Nela Pencea; XiaoChu Zhao; Stephen W Scherer; Cameron A Ackerley; Berge A Minassian
Journal:  Brain       Date:  2012-09       Impact factor: 13.501

8.  BATTEN DISEASE CAUSED BY A NOVEL MUTATION IN THE PPT1 GENE.

Authors:  Tatyana I Metelitsina; Darrel J Waggoner; Michael A Grassi
Journal:  Retin Cases Brief Rep       Date:  2016

Review 9.  Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy.

Authors:  Nicola Specchio; Alessandro Ferretti; Marina Trivisano; Nicola Pietrafusa; Chiara Pepi; Costanza Calabrese; Susanna Livadiotti; Alessandra Simonetti; Paolo Rossi; Paolo Curatolo; Federico Vigevano
Journal:  Drugs       Date:  2021-01       Impact factor: 9.546

10.  Rare variants in the neuronal ceroid lipofuscinosis gene MFSD8 are candidate risk factors for frontotemporal dementia.

Authors:  Ethan G Geier; Mathieu Bourdenx; Nadia J Storm; J Nicholas Cochran; Daniel W Sirkis; Ji-Hye Hwang; Luke W Bonham; Eliana Marisa Ramos; Antonio Diaz; Victoria Van Berlo; Deepika Dokuru; Alissa L Nana; Anna Karydas; Maureen E Balestra; Yadong Huang; Silvia P Russo; Salvatore Spina; Lea T Grinberg; William W Seeley; Richard M Myers; Bruce L Miller; Giovanni Coppola; Suzee E Lee; Ana Maria Cuervo; Jennifer S Yokoyama
Journal:  Acta Neuropathol       Date:  2018-10-31       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.